with: either 1) the inactivation of tumour suppressor genes (in men1, men4, fiPh, and hPT-JT); or 2) the activation of oncogenes with an increase of cellular proliferation (in men2a); or 3) the disregulation of the calcium set point with loss of the normal feedback control on PTh secretion (in fhh, admh and nshPT) (Tables 2 and 3 ). Genetic diagnosis of these forms is the gold standard for the correct diagnosis, the surveillance of the proband and his/her relatives, the appropriate choice of treatment and the timing and type of surgery. that encodes a 610-amino acid protein (menin protein). HPT is the first endocrinopathy to be diagnosed in 60% of men1 affected patients and the most frequent one [2] . men1 hPT has a penetrance of nearly 100% at age 50 and in contrast with the mean age of 55 years for the sporadic counterpart, its age of onset is usually 20-25 years [2] . men1 related hPT is characterized by a long asymptomatic phase followed by aspecific and variable manifestations such as asthenia, anorexia, psychiatric symptoms, costipation, polyuria, polidipsia, and osteopenia. however, it is important to remark that in the gene carriers men1-hPT is responsable of a detectable bone mass decrease at age 35 [3] . as in sporadic hPT, diagnosis is performed in the presence of hypercalcemia, with elevated serum levels of ionized calcium and of parathyroid hormone (PTh) or even if the values of circulating PTh are within the normal range. however, the genetic test is the gold standard to confirm MEN1 diagnosis.
Parathyroid glands involvement is asynchronous and asymmetrical with a variable volume enhancement with a maximum/minimum mean volume ratio of 9.6 [4] . macroscopically normal parathyroid glands are present in a range from 12% to 55%, and sometimes the intraoperative findings may be similar to those of the sporadic hPT with just one or two enlarged glands [5, 6, 56] . Furthermore, it is quite difficult to establish if a macroscopically normal gland is or is not pathologic. in fact typical histological patterns of increased activity can be found in parathyroid glands of not affected subjects and, on the other hand, the same patterns can be diagnosed either as pathologic or normal according to the pathologist evaluations [7, 8] . another point to be considered is the frequence of supernumerary (up to 20% in men1-hPT) [56, 57] and ectopic glands, being often intrathymic, within the thyroid gland, in the anterior mediastinum or exceptionally in the pericardium [6, 9] . some reports described the presence of pathologic parathyroid nests (embryonic parathyroid remnants) embedded within the fat tissue surrounding the trachea, the esophagus, and the carotid artery [9, 58, 59, 60] . no malignant progression is described for parathyroid glands in men1 affected patients.
Surgical Treatment
The early and late outcomes of surgical treatment of men1-hPT is generally worse than the one observed in sporadic hPT and it is basically due to recurrences either of macroscopically normal glands and of neoplastic remnants [10, 11] . The recurrence rate is strongly influenced by: a) the availability of a genetic and/or clinical diagnosis of men1; b) the surgeon's experience; c) the optimal surgical timing; d) the possibility to perform an intraoperative (histologic examination, and/or quick PTh assay) diagnosis, and e) the chosen surgical strategy.
first, the preoperative detection of MEN1 gene mutation must be obtained in the affected kindreds or when the clinical history is suggestive for men1 (i.e. young age). The molecular biology test can detect the mutation in nearly 90% of the affected patients [2] , with a preoperative diagnosis of men1 significantly reducing the rates of surgical failures [6, 12, 13] .
second, men1-hPT persistence rates correlate with the experience of surgeons working in high referral centres [14] .
Third, surgical timing in asymptomatic cases with mild hypercalcemia is still debated. it is not established if the guidelines followed for the asymptomatic hPT [15] should be followed also for men1-hPT. in fact postponing surgery for these patients may increase the chances of finding high volume parathyroid glands, with an easier and more effective surgery. on the other hand, the correction of hPT by prompt intervention is helpful in those asymptomatic patients who show a decrease in bone mineral density, being also associated with a lower complication rate and with benefits over other concomitant endocrinopathies, as hypergastrinemia [61] . Presently, genetic screening makes possible to monitor the biochemical behaviour and to address surgery before hPT related complications arise.
fourth, the role of intraoperative histologic examination is to confirm the presence of parathyroid tissue in the specimen, expecially in dubious cases, when ectopic or normally appearing glands are found. Histologic confirmation could be of value when grafting of fresh parathyroid tissue is programmed, making it possible to select fragments of tissue with normal histologic features.
fifth, quick intraoperative PTh measurement has become an important diagnostic tool in clinical practice to guide hPT surgery [16, 17] . its sensitivity in the surgical treatment of sporadic adenoma is nearly 95% [5, 17, 18] . When used for the discrimination of hPT due to hyperplasia or multiglandular disease, quick intraoperative PTh has shown a substantial-least 3-3 1/2 glands; and 3) total parathyroidectomy with transcervical thymectomy (TPTX) and autologous graft of parathyroid tissue.
1) Less than Subtotal Parathyroidectomy (LSPTX)
The involvement of parathyroid glands in men1-hPT is multiple and consequently the parathyroidectomy of just macroscopically enlarged glands bears higher risks of persistent or early recurrent hPT.
LSPTX is defined by the removal of 2-2 1/2 glands, leaving in situ 1 1/2 -2 unaffected glands which are marked with titanium clips or unabsorbable stitches, to make their identification easier in case of reoperation for persistent or recurrent hPT.
in the past, lsPTX had its supporters because of the reported higher rates of permanent hypoparathyroidsm in the case of radical surgery. This behaviour was justified by the evidence of the presence of some macroscopically normal glands, whose pathological progression was unpredictable in time. according to some authors, mild forms of men1 do exist, due to missense mutations of the gene responsable for a low penetrance of hPT within the affected kindred [19] . such cases might be treated in a conservative way [20] . however, this type of surgery was limited to cases where just one or two macroscopically enlarged glands could be localized, with the documentation of healthy tissue in intraoperative biopsies obtained from the normally appearing glands.
ly lower reliability with a high rate of false positive values [18, 68, 69] , probably due to the presence of suppressed pathological glands. in fact, 10 min after removal of the first pathological gland PTh values frequently decrease more than 50% from baseline. adopting other criteria, such as the evaluation at 20 min and a cut-off of 70%, Thompson et al. did not observe false positive cases [70] . in our opinion the main role of intraoperative PTH should be to confirm the removal of all the functional parathyroid tissue, so that the search for other parathyroid glands can be stopped and the graft of fresh parathyroid tissue performed. finally, even if the gold standard criterion for a successful total parathyroidectomy is not yet established, in our experience step by step venous sampling after the removal of each parathyroid gland up to reaching PTh values practically undetectable (i.e. near to the sensitivity of the adopted PTh assay) is a reliable approach to mark an effective parathyroidectomy [17] .
Surgical Options
The aims of surgery are to: 1) permanently correct hypercalcemia preventing persistent or recurrent hPT; 2) avoid persistent hypoparathyroidism; and 3) facilitate the surgical treatment of possible recurrences.
The various surgical approaches encompass: 1) less than subtotal parathyroidectomy (lsPTX) with only removal of macroscopically enlarged gland/s; 2) subtotal parathyroidectomy (sPTX) with removal of at patient to the risk of seeding affected cells in the nearest structures, thus harbouring the possibility of a cervical recurrence of hPT [29] . all these considerations may explain the poor outcomes shown in the different published series, with high rates of persistent and early recurrent hPT and of permanent hypoparathyroidism (Table 5) [5, 6, 14, 20-22, 25-28, 30-35, 61, 62] .
3) Total Parathyroidectomy (TPTX)
This procedure consists in a total parathyroidectomy with transcervical thymectomy and autologous transplantation of parathyroid tissue. aim of this technique is to radically remove all the parathyroid tissue including the occult gland(s) potentially present within the thymus and in the surrounding fat tissue, in order to avoid cervical recurrences difficult to treat and to reduce the risk of permanent hypoparathyroidism by the means of a graft in the nondominant forearm. Thymectomy is also helpful in preventing thymic carcinoids possibly arising in the syndrome.
The graft can be obtained at the end of the operation from fresh autologous tissue preserved at 4°c in ringer lactate solution or days later (once ascerin men1, lsPTX is always associated to much higher persistence/recurrence rates, than other more radical surgical procedures (Table 4) [5, 6, 14, [20] [21] [22] [23] [24] [25] [26] [27] [28] 61] .
2) Subtotal Parathyroidectomy (SPTX)
This procedure is defined by the removal of 3 glands and of part of the fourth (usually the less involved one), preserving not more than 50 mg of parathyroid tissue. The fourth gland can also be completely preserved if normal in volume. The sPTX is adopted with the main aim of avoiding permanent hypoparathyroidism and also reducing the risk of early postoperative hypocalcemia. on the other hand many criticisms were raised about sPTX, because in most cases all the parathyroid glands were found to be pathologic and it was difficult to establish which was the less involved gland to be preserved. This was even more true in the case of ectopic (intrathymic or intrathyroid glands). furthermore, the decision of how much tissue should be preserved is difficult, mostly in the case of small glands which can be easily devascularizated after manipulation. finally, the sectioning of potentially pathologic glands can expose the 
Treatment of Persistent and Recurrent MEN1-HPT
in a considerable part (20%) of men1 patients suffering of persistent or recurrent hPT, a fourth parathyroid could not be found at surgery even when treated in higher specialized centers [20, 21] . When a fourth gland cannot be found after accurate research, some surgeons perform a thyroid lobectomy with the evidence of an ectopic intrathyroid parathyroid in 33% of the cases [28] . differently than in sporadic primary hPT (1-2%) and secondary hPT (12%), in men1 there is not evidence of persistent or recurrent-hPT caused by parathyreomatosis [63, 64, 65] . The managing a recurrence/persistence of HPT is always difficult. first of all, the cause of the recurrence should be established and it can depend on one or more residual glands either within the neck or in the upper mediastinum. it is also very helpful to know all the available data about the operation, in order to undertake an accurate localization of the site of recurrence. if a forearm graft is present, circulating PTh levels should be monitored after arm ischemia for 30' by a tourniquet, in order to establish if such values decrease until they become undetectable [43] . in the case of reoperation, due to the high risk of nerve injury, surgery is indicated only when the recurrence is symptomatic, with high calcium urinary loss and significative bone mass reduction.
in the case of cervical or mediastinal recurrence, tained hPT is cured and PTh circulating levels are dramatically decreased or not detectable) using cryopreserved tissue according to the technique described by sonoda et al. [36] and Wells et al. [37] . The tissue to graft should be chosen from the most normal appearing gland in volume, colour and texture and after histological confirmation of its nature. Fragments to graft should be 1mm 3 and the smallest possible to avoid graft necrosis [38] . The optimal site where to graft is generally represented by the brachio-radialis muscle of the nondominant forearm. This procedure will make possible to monitor the success of the autotransplantation, through blood sampling taken bilaterally from each basilic vein to measure PTh levels. in brief, after incision of the fascia of the brachio-radialis muscle, its fibres are bluntly divided in order to create small spaces in which to embed 2-3 fragments of parathyroid tissue. The fascia is then sutured using nonabsorbable material to mark the site. The number of fragments to graft is still debated with various reports in the medical literature. commonly 20-25 fragments (or more in case of cryopreserved tissue) were considered to represent the optimal number [41] . other series reported 5-10 transplanted fragments [30, 40] , but with higher rates (50-60%) of non-working grafts, either with fresh or cryopreserved parathyroid tissue [41] (Tab. Vi) [14, 22, 24-26, 28, 37, 42, 61, 62] . it is still unclear whether the success rate is associated with the technical performance or with the parathyroid histopathology. interestingly, no permanent hypoparathyroidism or a rapid parathyroid function restoration was observed by Janson and Tisell after grafting parathyroid tissue within the abdominal subcutaneous fat in 7 are described. finally, hPT is exceptional in men2b syndrome [2] . some findings support the evidence of a relationship between RET mutations at codon 634 and hPT [46, 47] . it has been often observed how hPT is more frequently reported in some kindreds, whilst it cannot be detected in other kindreds even after a follow up, of 15 years and more from total thyroidectomy. This cannot be explained on genetic grounds, but by the fact that thyroidectomy can reduce the risk of hPT development either through the excision or the damage of parathyroid glands, or through limiting the production of calcitonin, a stimulating factor for PTh production through induced procalcitonin [48, 49] . moreover, in men2-hPT is often asymptomatic, with some patients showing normal circulating PTh values even if pathologic parathyroid glands are found at surgery. in 75%-80% of patients the diagnosis of hPT occurs synchronously with the diagnosis of mTc or pheochromocitoma, in the remainder ones hPT can be detected years after total thyroidectomy [2] . in less than 5% of cases diagnosis of hPT is made before that mTc or pheochromocitoma are diagnosed [51] .
hPT is recognized at a median age of 38 years, ranging from 7 to 71 years [6, 50, 51] and even if no parathyroid glands pathology is reported in patients who underwent prophylactic total thyroidectomy in pediatric or juvenile age [52, 53] , we described a case of a 5 years old men2 child who showed a pathologic parathyroid gland, when he underwent prophylactic total thyroidectomy. in 27%-48% of cases just one enlarged gland can be found during surgical exploration of the neck [6, 32, 51, 54] , while a double adenoma can be found in 8% of cases [50, 54] . in the other cases patterns similar to multiglandular disease or hyperplasia were described in 48% of the patients [50, 54] . even in this particular case of hPT, ectopic (generally intrathymic or mediastinal (up to the 43% of cases) or supernumerary glands (8.6%) are reported [50] .
Surgical Treatment
The overall experience about this kind of hPT is quite small and generally based on clinical reviews lacking long term follow-up programs. The surgical strategy is generally represented by the excision of the macroscopically enlarged glands found at surgery. The outcomes of partial parathyroidectomy with a follow-up ranging from 3.5 to 11.4 years showed the whole residual parathyroid tissue found at surgery should be removed, with a following heterotopic autologous transplantation. This technique allows very low risks of persistent hPT (none over 13 patients in the hellmann's experience), even lower when compared with a series of 11 patients (2 cases of persistent HPT) treated by SPTX [26] . Once a first recurrence is experienced, patients usually exhibit further recurrences earlier and more often. after TPTX with autograft, 38% and 36% recurrence rates are reported respectevely by helmann et al. [26] and Kivlen et al. [18] . another possible choice for these patients, after adequate informed consent, is represented by TPTX without autograft and lifelong substitutive therapy with calcium and vitamin d.
if a recurrence is diagnosed at the graft site, the removal of extra tissue is the treatment of choice, even if brilliant results cannot be always achieved, with a 42% curative rate in the Kivlen's experience [18] .
recently, a pharmacological approach was proposed for the cure of primary or secondary sporadic hPT by the introduction of calcimimetics, a new class of drugs with the property of reducing PTh release [44, 45] . it is still unclear whether these newly synthetized molecules can really stop or decrease parathyroid tumors' growth in men1 patients. multiple endocrine Neoplasia type 2 (meN2) related hPt men2 syndrome is a rare autosomal dominant inherited disease, caused by activating mutations within the RET gene and characterized by high penetrance for medullary thyroid cancer (mTc). RET gene is a proto-oncogene located in the proximal region of the long arm of chromosome 10. This gene encodes for a tyrosine kinase receptor. mutations in the RET gene traduces a dominant transformed protein with oncogenic activity. men2a syndrome is the most frequent form, mTc is present in 90% of the gene carriers, while bi-or uni-lateral pheochromocitoma is observed in 50% of patients and hPT in 20-30% [2] . also in the other men2a variants, represented by men2a with cutaneous amyloidotic lichen and by or men2a associated with hirschrprung disease, hPT is reported with a similar incidence. conversely, in the case of familial medullary thyroid carcinoma only (fmTc), no other endocrinopathies including primary (hPT) control of the course of the disease.
however, definitive cure for hPT is still to be achieved in men1, even when patients are treated in specialized centers dedicated to the study of this disease. data from the Genem (study group for men1 in the french speaking countries) showed that besides the growing number of sPTXs with thymectomy, 20% of men1 patients were still hypercalcemic soon after surgery [20] .
The choice between sPTX and TPTX is still a debated argument since no randomized trials are available at the moment and the present literature is mostly made up: a) by retrospective analysis with a low number of patients enrolled operated on by surgeons working in referral centers for endocrine pathology or b) data taken from national databases from heterogeneous surgeons. These facts together with the short follow-up in the various experiences make difficult a final interpretation of the avalaible data.
results from our personal experience indicate surgery for symptomatic patients with diagnosis of men1 genetically confirmed. surgery must be as radical as possible, following the indications obtained through the intraoperative PTh dosage. The graft should be prepared at the end of the cervical operation, in order to use fresh parathyroid tissue. The number of fragments to graft, obtained by the most normally appearing gland, should be carefully balanced either considering the need of its appropriate functioning and the risk of hPT recurrence due to graft overgrowth. a smaller number of fragments is probably a better choice, considering that hypoparathyroidism, which can be managed by supplementary doses of Vitamin d, is to be preferred to peristant or recurrent hPT.
hPT recurrence in 21% of the cases (Table 7) [21, 27, 50, 51, 54] . The need for a central neck compartment lymphadenectomy (thymectomy included in most cases) may lead to the unintentional excision or devascularization of some residual glands or of all of them. his is confirmed by the evidence of high rate (10-19%) of permanent hypoparathyroidism (Table 7) [21, 27, 50, 51, 54] .
The apparently favourable results after limited parathyroidectomy, should be evaluated after longer follow-up to clearly establish if this form of hPT is really a milder one, with lower recurrence rates and treatable by limited surgery.
few patients underwent sPTX and TPTX with autograft, with comparable results in terms of hPT recurrence and of hypoparathyroidism to those observed after more conservative surgery (Table 7) [21, 27, 50, 51, 54] .
at the present moment prophylactic parathyroidectomy at mTc surgery is not justified, even if some authors excise the parathyroid glands at the same time of the thyroidectomy with autograft of about 20 fragments of parathyroid tissue in the forearm [52, 55] . This procedure allows simpler and more accurate limphadenectomy avoiding the risk of leaving "in situ" pathologic glands. Good functioning of the graft is reported after such a procedure [52, 55] .
Conclusions for meN1 and meN2 syndromes
Today, better knowledge of the men1 syndrome and the real chance of the genetic diagnosis allow both on earlier intervention than in the past and a better [21] , raue f et al. [51] , herfarth et al. [50] , Kraimps et al. [54] , dotzenrath et al. [27] . °follow-up (yrs) 3,5-11,4.
identified and are prevalently localized in the calcium binding site of the extracellular domain of the receptor [71] . The inactivation of the G protein-coupled receptor results in half-maximal inhibition of PTh secretion only at high concentrations of serum calcium [72] . fhh is characterized by mild elevation of serum calcium concentrations, moderate hypophosphatemia, mild hypermagnesemia, lower urinary calcium excretion, and increased/normal circulating PTh levels. Patients are usually asymptomatic and fhh is not associated with osteopenia or with the renal complications of hypercalcemia, since the calcium mobilized from the bones by the overactive parathyroids glands is reabsorbed by an increased tubular renal function.
rarely, different clinical presentation of fhh is possible with osteomalacia in the presence of hyposphosphatemia [73] ; and with hypercalciuria, renal stones and single or multiple parathyroid adenoma. These features are recognized as autosomal dominant mild hyperparathyroidism/admh [74] . in these patients surgery can be indicated : subtotal parathyroidectomy leaving 10-20 mg of parathyroid tissue or total parahtyroidectomy with autotransplantation normalize calcium and PTh and can provide a long-term resolution of the syndrome [75] . it is not completely clear if this was a simple causality due to the occurrence of adenomatous transformations of parathyroid glands or a consequence the mutation in the casr gene [76] .
in fhh the differential diagnosis from other forms of primary hPT is based on the family history, renal calcium excretion (<150 mg/day), calcium/creatinine clearance ratio (<0.020), and CASR gene analysis [77] . Parathyroid glands in the setting of fhh are only slightly enlarged. a peculiar histological aspect of the parathyroid glands described in some fhh patients is lipohyperplasia [78] . This histological feature is considered indicative of fhh and it is indicative for the need of searching CaSR gene mutations [79] . in general, medical or surgical treatment is not indicated in fhh, as the clinical course of the disease is benign and neck exploration surgery with removal of one or more parathyroid glands does not cure the disorder [73] .
Neonatal severe hyperparathyroidism (NshPt)
The homozygous or compound heterozygous variants of inactivating mutations of the CaSR gene are conversely, a less radical approach is suggested in case of men2, since hPT is less frequently expressed and it involves all the 4 parathyroids in less than 50% of cases [2] .
multiple endocrine Neoplasia type 4 (meN4)
Recently, a new MEN syndrome has been identified in the rodents and in the humans by Pellegata et al., [66, 67] . They described a recessive men-like syndrome (men X) in the rat, with a phenotypic overlap of both MEN1 and MEN2 and identified a germ-line mutation in a tumour suppressor gene CDKN1B, encoding for the cyclin dependent kinase inhibitor p27 [66, 67] . The p27 protein regulates the cell cycle progression by inhibiting cyclin/cdk complexes and it is determinant in proliferation and differentiation processes [66, 67] . affected animals developed bilateral pheochromocytomas and parathyroid adenomas, multifocal thyroid c cell hyperplasia, paragangliomas, and endocrine pancreatic hyperplasia. in addition, affected animals developed bilateral cataracts in the first few weeks of life. at present, two females are the index patients with men4 syndrome [66, 67] . in both the patients inactivating mutations in the CDKN1B gene have been identified with production of truncated p27 protein [66, 67] . one patient developed acromegaly, and primary hyperparathyroidism [66] . The clinical features of other patients were characterized by small-cell neuroendocrine cervical carcinoma, acThsecreting pituitary adenoma (cushing's disease), and hyperparathyroidism [67] . further genetic studies and the recognition of other cases of men4 will allow to better characterize this pathology.
Familial hypocalciuric hypercalcemia (Fhh)
and Neonatal severe hyperparathyroidism (NshPt)
fhh is an inherited autosomal dominant disorder due to inactivating mutations of the CASR gene which encodes the calcium sensing receptor, capable to sense small changes in circulating calcium concentrations both at the parathyroid and kidney level. all affected individuals are heterozygous for the mutation of the CASR. approximately two hundred mutations in the CASR gene, sited at chromosome 3q13-21, have been in females has been reported [68] and parathyroid carcinoma may occur in approximately 10-15% of affected individuals [18, 83] .
When compared to men1-related hPT, hPT-JT syndrome may be uniglandular and may run with a more aggressive course. The patients tend to have more severe hypercalcemia and hypercalcemic crisis could represent the first clinical manifestation of the disorder. in order to monitor the presence/absence of hPT, beginning by 15 years of age hPT-JT patients should undergo annual blood test evaluating ionized calcium and intact parathyroid hormone (iPTh) levels. moreover, due to the potential severity involvement of other organs, in these patients, maxilla, mandible, kidney, and uterine lesions, expecially in young subjects, should be carefully monitored by imaging studies (i.e. orthopantography of the face, every 3 years and annual abdominal ultrasound or computed tomography scan).
Genetic features
recently, the HRPT2 gene was recognized as responsible for this syndrome, and identified as a "tumour suppressor gene" encoding the protein parafibromin (Table 2) . This gene appears to be involved also in the pathogenesis of sporadic forms of primary hPT. over 60 germline inactivating mutations of HRPT2 have been so far ( Table 2 ).
The protein encoded by the HRPT2 gene is of 531 amino acids, and it is responsible for the development of parathyroid tumours and ossifying fibromas. To date, the protein doesn't exhibit any homology to known protein domains. The gene appears to be ubiquitously expressed in several human tissues such as the kidney, the heart, the liver, the pancreas, the skeletal muscles, the brain, and the lung [18] . however, its role in development and tumorigenesis still remains to be elucidated.
loss of wild-type alleles in hPT-JT syndrome was found both in renal [68] and parathyroid tumours [75] . These findings, together with the inactivating nature of the germline mutations strongly suggest a tumour suppressive role of parafibromin.
The possibility to perform dna test provides the great opportunity for an early identification of an asymptomatic gene carrier who will receive the needed clinical screening since parathyroid carcinoma is difficult to diagnose. responsible of nshPT. nshPT is quite uncommon among fhh families and since generally it is the consequence of fhh consanguineous unions, it is interpreted as an autosomal recessive disorder [80] . however, a single abnormal allele in the CaSR gene has also been described as responsible of nshPT [81] .
nshPT in most cases appears in the first days of life. The hallmarks of the disease are hypotonia, poor feeding, polyuria, dehydration, failure to thrive and bony changes that usually lead to pathological multiple fractures. Typically a "flail chest" is present in relationship to fractures in the ribs and this complication causes decreased thoracic excursions and respiratory distress. both serum calcium and PTh are markedly elevated and a relative hypocalciuria is present. if left untreated, the disease causes a devastating neurodevelopmental disorder and becomes rapidly lethal.
The treatment of choice is total parathyroidectomy without parathyroid fragment implants which is the only definitive cure of the severe type of this disorder. however, the availability of genetic testing of the CaSR gene (even detecting homozygous inactivating mutations) has recently showed that there are other less severe clinical presentations of neonatal hyperparathyroidism with a different natural history and characterized by an asymptomatic course until adulthood [73] . in these cases surgery could be avoided and the use of calcimimetics is indicated.
hyperparathyroidism-Jaw tumors (hPt-Jt) syndrome
hPT-JT syndrome is a rare autosomal dominantly inherited disorder characterized by primary hPT and fibrous-osseous tumours of the mandible and/or the maxilla (ossifying fibroma). More than 15% of these patients may also develop Wilms'tumour, papillary renal carcinoma, polycystic kidney disease, renal cysts, and uterine abnormalities. The PhPT exhibits an aggressive behaviour and it is frequently sustained by parathyroid carcinoma [18, 82] .
in the context of hPT-related syndrome, hPT-JT syndrome is one of the least common, although not less interesting or important (Table 1) .
about 80% of patients present with hPT [18] , that may develop in late adolescence or in older patients (mean age 32 years), with hPT being the most common feature of the syndrome. a reduced penetrance nition fihPT is characterised by hPT not associated with the presence of other endocrine tumours [91] .
Genetic features
most cases of fihPT have been recently linked to germ-line inactivating mutations of the HRPT2 gene [87, 92, 93] . fihPT has been also linked to mutations in the MEN1 and in the CASR genes [91] . most of fihPT kindreds have currently an unknown genetic background. To date, approximately over 100 fihPT families have been described.
Pathology
fihPT is characterized by the presence of benign uniglandular (singular adenoma) or multiglandular (hyperplasia) parathyroid disease that represents the most frequent pathological feature underlying the parathyroid hyperfunction [90, 94] . This parathyroid disease is associated with high risk of progression to malignancy [95] . The most recent literature reports a parathyroid carcinoma prevalence of 8.4-18% [87, 88, 89] .
Treatment
The treatment of choice is surgery. The extent of the parathyroid resection for treatment of fihPT is a controversial issue. in literature multiglandular disease rate is reported as high as 45% to 75% [90, 94, 95] . on the basis of the frequency of multiglandular disease, many surgeons prefer an aggressive surgical approach with 3.5-gland resection or total parathyroidectomy with autotransplantation [90, 95, 96] . on the other hand, it has been observed that fihPT in patients with HRPT2 mutations is often characterized by singlegland involvement and several studies have shown that fihPT is successfully treated for many years with excision of a single hyperfunctioning gland [89, 90, 94, 95] . in fact, longterm remission up to 34 years after single resections has been reported [90] . moreover, by uniglandular resections there is no risk of hypoparathyroidism, while the radical operative approache is characterized by high incidence of postoperative permanent hypoparathyroidism varying in the literature between 13% and 41% [90] . it is also important to note that the incidence of multiglandular disease in the patients with fihPT is overestimated as the patients studied included not only subjects with fihPT but also unrecPathology hPT in hPT-JT syndrome generally consists of involvement of one or two parathyroid glands (adenoma or double adenoma) ( Table 3 ) that may be or may be not synchronously present [75] , differently from the men1-hPT in which all glands are involved. Parathyroid carcinoma may occur in approximately 10-15% of affected individuals [18, 83] .
The high incidence of cystic features in resected parathyroid glands represents a classical indication of the nature of parathyroid neoplasia in hPT-JT syndrome. in fact, due to the frequent identification of parathyroid recurring cystic adenomas this clinical entity can be referred to also as familial cystic parathyroid adenomatosis ( Table 3 ). The jaw lesions typically associated to this syndrome have been reported to be histologically distinct from the typical ones representing the bone disease classically associated to PhPT [68] .
as the clinical diagnosis of hPT-JT syndrome is made, neck surgery should be promptly performed. no general consensus exists on which type of surgical approach should be adopted. The removal of the enlarged gland(s) with long-term follow-up is proposed, while others foresee TPTX followed by auto transplantation to the nondominant forearm has not been reached. for parathyroid carcinoma neck surgery, specifically an en bloc resection of primary tumour, with resection of omolateral thyroid lobectomy and of adjacent soft tissue, is the only curative treatment (Table 3) . dissection of the central compartment lymph nodes is also required in the presence of carcinoma, whereas the lateral dissection is performed when clinical and/ or radiological evidence of enlarged lymph nodes is present [84, 85] .
Familial isolated Primary hyperparathyroidism (FihPt)
first described in 1936 [86] , familial isolated primary hyperparathyroidism (fihPT) is a rare hereditary, autosomal-dominant disorder with variable expression and incomplete penetrance in early age [87] [88] [89] . fihPT seems to be a distinct entity, behaving differently from other heritable HPT syndromes [90] . By defi-of this surgical approach is confirmed by a recent report that showed in patients with uniglandular disease an operative success rate of 93% [90] . ognized men1 gene carriers [90] . because of these findings, a less aggressive surgical procedure is suggested in patients with fihPT, especially if guided by intraoperative PTh monitoring [89, 90] . The validity references
